X4 Pharmaceuticals has recently achieved a key milestone—its positive assessment opinion has been officially submitted to the European Commission for final review.
Show original
Market expectations suggest that the final approval decision for this important regulatory process is likely to be made in the second quarter of 2026. This progress marks the company's R&D achievements in the field of rare disease treatment moving one step closer to gaining access to the European market.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
BTC falls below $66,000, S&P 500 futures drop 1.4%
AIcoin•2026/03/02 09:23
Guotou Silver LOF: Trading suspended from market opening until 10:30 on March 3
汇通财经•2026/03/02 09:20
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$66,423.8
-0.26%
Ethereum
ETH
$1,959.23
-1.56%
Tether USDt
USDT
$1
-0.00%
BNB
BNB
$620.42
-0.33%
XRP
XRP
$1.36
-1.97%
USDC
USDC
$0.9999
+0.02%
Solana
SOL
$83.89
-1.97%
TRON
TRX
$0.2818
+0.12%
Dogecoin
DOGE
$0.09259
-1.70%
Cardano
ADA
$0.2732
-2.61%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now